 | • レポートコード：MRC2Q12-16859 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,470,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、切除不能肝細胞がん治療の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に切除不能肝細胞がん治療のグローバル市場のxxx％を占める「新規T細胞治療」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 切除不能肝細胞がん治療の中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの切除不能肝細胞がん治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 切除不能肝細胞がん治療のグローバル主要プレイヤーには、Pfizer Inc.、Eli Lilly、Bayer AG、Merck & Co. Inc.、Bristol-Myers-Squibb Company、Celgene Corporation、Eisai Co. Ltd、F. Hoffmann-La Roche Ltd、Chugai Pharmaceutical Co. Ltd、Pharmaxis、BeiGene、Astrazeneca PLCなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 切除不能肝細胞がん治療市場は、種類と用途によって区分されます。世界の切除不能肝細胞がん治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 新規T細胞治療、化学治療 【用途別セグメント】 病院、クリニック、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 切除不能肝細胞がん治療製品概要 - 種類別市場（新規T細胞治療、化学治療） - 用途別市場（病院、クリニック、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の切除不能肝細胞がん治療販売量予測2017-2028 - 世界の切除不能肝細胞がん治療売上予測2017-2028 - 切除不能肝細胞がん治療の地域別販売量 - 切除不能肝細胞がん治療の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別切除不能肝細胞がん治療販売量 - 主要メーカー別切除不能肝細胞がん治療売上 - 主要メーカー別切除不能肝細胞がん治療価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（新規T細胞治療、化学治療） - 切除不能肝細胞がん治療の種類別販売量 - 切除不能肝細胞がん治療の種類別売上 - 切除不能肝細胞がん治療の種類別価格 ・用途別市場規模（病院、クリニック、その他） - 切除不能肝細胞がん治療の用途別販売量 - 切除不能肝細胞がん治療の用途別売上 - 切除不能肝細胞がん治療の用途別価格 ・北米市場 - 北米の切除不能肝細胞がん治療市場規模（種類別、用途別） - 主要国別の切除不能肝細胞がん治療市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの切除不能肝細胞がん治療市場規模（種類別、用途別） - 主要国別の切除不能肝細胞がん治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の切除不能肝細胞がん治療市場規模（種類別、用途別） - 主要国別の切除不能肝細胞がん治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の切除不能肝細胞がん治療市場規模（種類別、用途別） - 主要国別の切除不能肝細胞がん治療市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの切除不能肝細胞がん治療市場規模（種類別、用途別） - 主要国別の切除不能肝細胞がん治療市場規模（トルコ、サウジアラビア） ・企業情報 Pfizer Inc.、Eli Lilly、Bayer AG、Merck & Co. Inc.、Bristol-Myers-Squibb Company、Celgene Corporation、Eisai Co. Ltd、F. Hoffmann-La Roche Ltd、Chugai Pharmaceutical Co. Ltd、Pharmaxis、BeiGene、Astrazeneca PLC ・産業チェーン及び販売チャネル分析 - 切除不能肝細胞がん治療の産業チェーン分析 - 切除不能肝細胞がん治療の原材料 - 切除不能肝細胞がん治療の生産プロセス - 切除不能肝細胞がん治療の販売及びマーケティング - 切除不能肝細胞がん治療の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 切除不能肝細胞がん治療の産業動向 - 切除不能肝細胞がん治療のマーケットドライバー - 切除不能肝細胞がん治療の課題 - 切除不能肝細胞がん治療の阻害要因 ・主な調査結果 |
Market Analysis and Insights: Global Unresectable Hepatocellular Carcinoma Treatment Market
The global Unresectable Hepatocellular Carcinoma Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Novel T Cell Therapy accounting for % of the Unresectable Hepatocellular Carcinoma Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Unresectable Hepatocellular Carcinoma Treatment market size is valued at US$ million in 2021, while the North America and Europe Unresectable Hepatocellular Carcinoma Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Unresectable Hepatocellular Carcinoma Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Unresectable Hepatocellular Carcinoma Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Unresectable Hepatocellular Carcinoma Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Unresectable Hepatocellular Carcinoma Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Unresectable Hepatocellular Carcinoma Treatment market.
Global Unresectable Hepatocellular Carcinoma Treatment Scope and Market Size
Unresectable Hepatocellular Carcinoma Treatment market is segmented by players, region (country), by Treatment Method and by Application. Players, stakeholders, and other participants in the global Unresectable Hepatocellular Carcinoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Treatment Method and by Application for the period 2017-2028.
Segment by Treatment Method
Novel T Cell Therapy
Chemotherapy
Segment by Application
Hospitals
Clinics
Others
By Company
Pfizer Inc.
Eli Lilly
Bayer AG
Merck & Co. Inc.
Bristol-Myers-Squibb Company
Celgene Corporation
Eisai Co. Ltd
F. Hoffmann-La Roche Ltd
Chugai Pharmaceutical Co. Ltd
Pharmaxis
BeiGene
Astrazeneca PLC
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Treatment Method
1.2.1 Global Unresectable Hepatocellular Carcinoma Treatment Market Size Growth Rate by Treatment Method, 2017 VS 2021 VS 2028
1.2.2 Novel T Cell Therapy
1.2.3 Chemotherapy
1.3 Market by Application
1.3.1 Global Unresectable Hepatocellular Carcinoma Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Unresectable Hepatocellular Carcinoma Treatment Market Perspective (2017-2028)
2.2 Unresectable Hepatocellular Carcinoma Treatment Growth Trends by Region
2.2.1 Unresectable Hepatocellular Carcinoma Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Unresectable Hepatocellular Carcinoma Treatment Historic Market Size by Region (2017-2022)
2.2.3 Unresectable Hepatocellular Carcinoma Treatment Forecasted Market Size by Region (2023-2028)
2.3 Unresectable Hepatocellular Carcinoma Treatment Market Dynamics
2.3.1 Unresectable Hepatocellular Carcinoma Treatment Industry Trends
2.3.2 Unresectable Hepatocellular Carcinoma Treatment Market Drivers
2.3.3 Unresectable Hepatocellular Carcinoma Treatment Market Challenges
2.3.4 Unresectable Hepatocellular Carcinoma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Unresectable Hepatocellular Carcinoma Treatment Players by Revenue
3.1.1 Global Top Unresectable Hepatocellular Carcinoma Treatment Players by Revenue (2017-2022)
3.1.2 Global Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Unresectable Hepatocellular Carcinoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Unresectable Hepatocellular Carcinoma Treatment Revenue
3.4 Global Unresectable Hepatocellular Carcinoma Treatment Market Concentration Ratio
3.4.1 Global Unresectable Hepatocellular Carcinoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Unresectable Hepatocellular Carcinoma Treatment Revenue in 2021
3.5 Unresectable Hepatocellular Carcinoma Treatment Key Players Head office and Area Served
3.6 Key Players Unresectable Hepatocellular Carcinoma Treatment Product Solution and Service
3.7 Date of Enter into Unresectable Hepatocellular Carcinoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Unresectable Hepatocellular Carcinoma Treatment Breakdown Data by Treatment Method
4.1 Global Unresectable Hepatocellular Carcinoma Treatment Historic Market Size by Treatment Method (2017-2022)
4.2 Global Unresectable Hepatocellular Carcinoma Treatment Forecasted Market Size by Treatment Method (2023-2028)
5 Unresectable Hepatocellular Carcinoma Treatment Breakdown Data by Application
5.1 Global Unresectable Hepatocellular Carcinoma Treatment Historic Market Size by Application (2017-2022)
5.2 Global Unresectable Hepatocellular Carcinoma Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Unresectable Hepatocellular Carcinoma Treatment Market Size (2017-2028)
6.2 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method
6.2.1 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022)
6.2.2 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028)
6.2.3 North America Unresectable Hepatocellular Carcinoma Treatment Market Share by Treatment Method (2017-2028)
6.3 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application
6.3.1 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022)
6.3.2 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028)
6.3.3 North America Unresectable Hepatocellular Carcinoma Treatment Market Share by Application (2017-2028)
6.4 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country
6.4.1 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022)
6.4.2 North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size (2017-2028)
7.2 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method
7.2.1 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022)
7.2.2 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028)
7.2.3 Europe Unresectable Hepatocellular Carcinoma Treatment Market Share by Treatment Method (2017-2028)
7.3 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Application
7.3.1 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022)
7.3.2 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028)
7.3.3 Europe Unresectable Hepatocellular Carcinoma Treatment Market Share by Application (2017-2028)
7.4 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Country
7.4.1 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022)
7.4.2 Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size (2017-2028)
8.2 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method
8.2.1 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022)
8.2.2 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028)
8.2.3 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Share by Treatment Method (2017-2028)
8.3 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Application
8.3.1 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Region
8.4.1 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size (2017-2028)
9.2 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method
9.2.1 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022)
9.2.2 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028)
9.2.3 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Share by Treatment Method (2017-2028)
9.3 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application
9.3.1 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Share by Application (2017-2028)
9.4 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country
9.4.1 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size (2017-2028)
10.2 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method
10.2.1 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022)
10.2.2 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028)
10.2.3 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Share by Treatment Method (2017-2028)
10.3 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Application
10.3.1 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Country
10.4.1 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Details
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Unresectable Hepatocellular Carcinoma Treatment Introduction
11.1.4 Pfizer Inc. Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.1.5 Pfizer Inc. Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Unresectable Hepatocellular Carcinoma Treatment Introduction
11.2.4 Eli Lilly Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.2.5 Eli Lilly Recent Developments
11.3 Bayer AG
11.3.1 Bayer AG Company Details
11.3.2 Bayer AG Business Overview
11.3.3 Bayer AG Unresectable Hepatocellular Carcinoma Treatment Introduction
11.3.4 Bayer AG Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.3.5 Bayer AG Recent Developments
11.4 Merck & Co. Inc.
11.4.1 Merck & Co. Inc. Company Details
11.4.2 Merck & Co. Inc. Business Overview
11.4.3 Merck & Co. Inc. Unresectable Hepatocellular Carcinoma Treatment Introduction
11.4.4 Merck & Co. Inc. Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.4.5 Merck & Co. Inc. Recent Developments
11.5 Bristol-Myers-Squibb Company
11.5.1 Bristol-Myers-Squibb Company Company Details
11.5.2 Bristol-Myers-Squibb Company Business Overview
11.5.3 Bristol-Myers-Squibb Company Unresectable Hepatocellular Carcinoma Treatment Introduction
11.5.4 Bristol-Myers-Squibb Company Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.5.5 Bristol-Myers-Squibb Company Recent Developments
11.6 Celgene Corporation
11.6.1 Celgene Corporation Company Details
11.6.2 Celgene Corporation Business Overview
11.6.3 Celgene Corporation Unresectable Hepatocellular Carcinoma Treatment Introduction
11.6.4 Celgene Corporation Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.6.5 Celgene Corporation Recent Developments
11.7 Eisai Co. Ltd
11.7.1 Eisai Co. Ltd Company Details
11.7.2 Eisai Co. Ltd Business Overview
11.7.3 Eisai Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Introduction
11.7.4 Eisai Co. Ltd Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.7.5 Eisai Co. Ltd Recent Developments
11.8 F. Hoffmann-La Roche Ltd
11.8.1 F. Hoffmann-La Roche Ltd Company Details
11.8.2 F. Hoffmann-La Roche Ltd Business Overview
11.8.3 F. Hoffmann-La Roche Ltd Unresectable Hepatocellular Carcinoma Treatment Introduction
11.8.4 F. Hoffmann-La Roche Ltd Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.8.5 F. Hoffmann-La Roche Ltd Recent Developments
11.9 Chugai Pharmaceutical Co. Ltd
11.9.1 Chugai Pharmaceutical Co. Ltd Company Details
11.9.2 Chugai Pharmaceutical Co. Ltd Business Overview
11.9.3 Chugai Pharmaceutical Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Introduction
11.9.4 Chugai Pharmaceutical Co. Ltd Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.9.5 Chugai Pharmaceutical Co. Ltd Recent Developments
11.10 Pharmaxis
11.10.1 Pharmaxis Company Details
11.10.2 Pharmaxis Business Overview
11.10.3 Pharmaxis Unresectable Hepatocellular Carcinoma Treatment Introduction
11.10.4 Pharmaxis Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.10.5 Pharmaxis Recent Developments
11.11 BeiGene
11.11.1 BeiGene Company Details
11.11.2 BeiGene Business Overview
11.11.3 BeiGene Unresectable Hepatocellular Carcinoma Treatment Introduction
11.11.4 BeiGene Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.11.5 BeiGene Recent Developments
11.12 Astrazeneca PLC
11.12.1 Astrazeneca PLC Company Details
11.12.2 Astrazeneca PLC Business Overview
11.12.3 Astrazeneca PLC Unresectable Hepatocellular Carcinoma Treatment Introduction
11.12.4 Astrazeneca PLC Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
11.12.5 Astrazeneca PLC Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
Table 1. Global Unresectable Hepatocellular Carcinoma Treatment Market Size Growth Rate by Treatment Method (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Novel T Cell Therapy
Table 3. Key Players of Chemotherapy
Table 4. Global Unresectable Hepatocellular Carcinoma Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global Unresectable Hepatocellular Carcinoma Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Unresectable Hepatocellular Carcinoma Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Unresectable Hepatocellular Carcinoma Treatment Market Share by Region (2017-2022)
Table 8. Global Unresectable Hepatocellular Carcinoma Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Unresectable Hepatocellular Carcinoma Treatment Market Share by Region (2023-2028)
Table 10. Unresectable Hepatocellular Carcinoma Treatment Market Trends
Table 11. Unresectable Hepatocellular Carcinoma Treatment Market Drivers
Table 12. Unresectable Hepatocellular Carcinoma Treatment Market Challenges
Table 13. Unresectable Hepatocellular Carcinoma Treatment Market Restraints
Table 14. Global Unresectable Hepatocellular Carcinoma Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Unresectable Hepatocellular Carcinoma Treatment Revenue Share by Players (2017-2022)
Table 16. Global Top Unresectable Hepatocellular Carcinoma Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Unresectable Hepatocellular Carcinoma Treatment as of 2021)
Table 17. Ranking of Global Top Unresectable Hepatocellular Carcinoma Treatment Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Unresectable Hepatocellular Carcinoma Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Unresectable Hepatocellular Carcinoma Treatment Product Solution and Service
Table 21. Date of Enter into Unresectable Hepatocellular Carcinoma Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022) & (US$ Million)
Table 24. Global Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share by Treatment Method (2017-2022)
Table 25. Global Unresectable Hepatocellular Carcinoma Treatment Forecasted Market Size by Treatment Method (2023-2028) & (US$ Million)
Table 26. Global Unresectable Hepatocellular Carcinoma Treatment Revenue Market Share by Treatment Method (2023-2028)
Table 27. Global Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Unresectable Hepatocellular Carcinoma Treatment Revenue Share by Application (2017-2022)
Table 29. Global Unresectable Hepatocellular Carcinoma Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Unresectable Hepatocellular Carcinoma Treatment Revenue Share by Application (2023-2028)
Table 31. North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022) & (US$ Million)
Table 32. North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028) & (US$ Million)
Table 33. North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 34. North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 35. North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022) & (US$ Million)
Table 38. Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028) & (US$ Million)
Table 39. Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 40. Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 41. Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 42. Europe Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 43. Asia Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022) & (US$ Million)
Table 44. Asia Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028) & (US$ Million)
Table 45. Asia Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 49. Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022) & (US$ Million)
Table 50. Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028) & (US$ Million)
Table 51. Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 52. Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 53. Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 54. Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2017-2022) & (US$ Million)
Table 56. Middle East and Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Treatment Method (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Unresectable Hepatocellular Carcinoma Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 61. Pfizer Inc. Company Details
Table 62. Pfizer Inc. Business Overview
Table 63. Pfizer Inc. Unresectable Hepatocellular Carcinoma Treatment Product
Table 64. Pfizer Inc. Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 65. Pfizer Inc. Recent Developments
Table 66. Eli Lilly Company Details
Table 67. Eli Lilly Business Overview
Table 68. Eli Lilly Unresectable Hepatocellular Carcinoma Treatment Product
Table 69. Eli Lilly Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 70. Eli Lilly Recent Developments
Table 71. Bayer AG Company Details
Table 72. Bayer AG Business Overview
Table 73. Bayer AG Unresectable Hepatocellular Carcinoma Treatment Product
Table 74. Bayer AG Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 75. Bayer AG Recent Developments
Table 76. Merck & Co. Inc. Company Details
Table 77. Merck & Co. Inc. Business Overview
Table 78. Merck & Co. Inc. Unresectable Hepatocellular Carcinoma Treatment Product
Table 79. Merck & Co. Inc. Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 80. Merck & Co. Inc. Recent Developments
Table 81. Bristol-Myers-Squibb Company Company Details
Table 82. Bristol-Myers-Squibb Company Business Overview
Table 83. Bristol-Myers-Squibb Company Unresectable Hepatocellular Carcinoma Treatment Product
Table 84. Bristol-Myers-Squibb Company Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 85. Bristol-Myers-Squibb Company Recent Developments
Table 86. Celgene Corporation Company Details
Table 87. Celgene Corporation Business Overview
Table 88. Celgene Corporation Unresectable Hepatocellular Carcinoma Treatment Product
Table 89. Celgene Corporation Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 90. Celgene Corporation Recent Developments
Table 91. Eisai Co. Ltd Company Details
Table 92. Eisai Co. Ltd Business Overview
Table 93. Eisai Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Product
Table 94. Eisai Co. Ltd Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 95. Eisai Co. Ltd Recent Developments
Table 96. F. Hoffmann-La Roche Ltd Company Details
Table 97. F. Hoffmann-La Roche Ltd Business Overview
Table 98. F. Hoffmann-La Roche Ltd Unresectable Hepatocellular Carcinoma Treatment Product
Table 99. F. Hoffmann-La Roche Ltd Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 100. F. Hoffmann-La Roche Ltd Recent Developments
Table 101. Chugai Pharmaceutical Co. Ltd Company Details
Table 102. Chugai Pharmaceutical Co. Ltd Business Overview
Table 103. Chugai Pharmaceutical Co. Ltd Unresectable Hepatocellular Carcinoma Treatment Product
Table 104. Chugai Pharmaceutical Co. Ltd Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 105. Chugai Pharmaceutical Co. Ltd Recent Developments
Table 106. Pharmaxis Company Details
Table 107. Pharmaxis Business Overview
Table 108. Pharmaxis Unresectable Hepatocellular Carcinoma Treatment Product
Table 109. Pharmaxis Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 110. Pharmaxis Recent Developments
Table 111. BeiGene Company Details
Table 112. BeiGene Business Overview
Table 113. BeiGene Unresectable Hepatocellular Carcinoma Treatment Product
Table 114. BeiGene Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 115. BeiGene Recent Developments
Table 116. Astrazeneca PLC Company Details
Table 117. Astrazeneca PLC Business Overview
Table 118. Astrazeneca PLC Unresectable Hepatocellular Carcinoma Treatment Product
Table 119. Astrazeneca PLC Revenue in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022) & (US$ Million)
Table 120. Astrazeneca PLC Recent Developments
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Unresectable Hepatocellular Carcinoma Treatment Market Share by Treatment Method: 2021 VS 2028
Figure 2. Novel T Cell Therapy Features
Figure 3. Chemotherapy Features
Figure 4. Global Unresectable Hepatocellular Carcinoma Treatment Market Share by Application: 2021 VS 2028
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Others Case Studies
Figure 8. Unresectable Hepatocellular Carcinoma Treatment Report Years Considered
Figure 9. Global Unresectable Hepatocellular Carcinoma Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Unresectable Hepatocellular Carcinoma Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Unresectable Hepatocellular Carcinoma Treatment Market Share by Region: 2021 VS 2028
Figure 12. Global Unresectable Hepatocellular Carcinoma Treatment Market Share by Players in 2021
Figure 13. Global Top Unresectable Hepatocellular Carcinoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Unresectable Hepatocellular Carcinoma Treatment as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Unresectable Hepatocellular Carcinoma Treatment Revenue in 2021
Figure 15. North America Unresectable Hepatocellular Carcinoma Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 16. North America Unresectable Hepatocellular Carcinoma Treatment Market Size Market Share by Treatment Method (2017-2028)
Figure 17. North America Unresectable Hepatocellular Carcinoma Treatment Market Size Market Share by Application (2017-2028)
Figure 18. North America Unresectable Hepatocellular Carcinoma Treatment Market Size Share by Country (2017-2028)
Figure 19. United States Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Unresectable Hepatocellular Carcinoma Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 22. Europe Unresectable Hepatocellular Carcinoma Treatment Market Size Market Share by Treatment Method (2017-2028)
Figure 23. Europe Unresectable Hepatocellular Carcinoma Treatment Market Size Market Share by Application (2017-2028)
Figure 24. Europe Unresectable Hepatocellular Carcinoma Treatment Market Size Share by Country (2017-2028)
Figure 25. Germany Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 32. Asia Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size Market Share by Treatment Method (2017-2028)
Figure 33. Asia Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size Market Share by Application (2017-2028)
Figure 34. Asia Pacific Unresectable Hepatocellular Carcinoma Treatment Market Size Share by Region (2017-2028)
Figure 35. China Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Japan Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. South Korea Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Southeast Asia Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. India Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Australia Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 41. Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 42. Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size Market Share by Treatment Method (2017-2028)
Figure 43. Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size Market Share by Application (2017-2028)
Figure 44. Latin America Unresectable Hepatocellular Carcinoma Treatment Market Size Share by Country (2017-2028)
Figure 45. Mexico Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Brazil Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Middle East & Africa Unresectable Hepatocellular Carcinoma Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 48. Middle East and Africa Unresectable Hepatocellular Carcinoma Treatment Market Size Market Share by Treatment Method (2017-2028)
Figure 49. Middle East and Africa Unresectable Hepatocellular Carcinoma Treatment Market Size Market Share by Application (2017-2028)
Figure 50. Middle East and Africa Unresectable Hepatocellular Carcinoma Treatment Market Size Share by Country (2017-2028)
Figure 51. Turkey Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Saudi Arabia Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. UAE Unresectable Hepatocellular Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Pfizer Inc. Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 55. Eli Lilly Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 56. Bayer AG Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 57. Merck & Co. Inc. Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 58. Bristol-Myers-Squibb Company Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 59. Celgene Corporation Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 60. Eisai Co. Ltd Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 61. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 62. Chugai Pharmaceutical Co. Ltd Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 63. Pharmaxis Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 64. BeiGene Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 65. Astrazeneca PLC Revenue Growth Rate in Unresectable Hepatocellular Carcinoma Treatment Business (2017-2022)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed